KOSDAQBiotech & Pharma102940

Kolon Life Science

₩11,440▼ 0.44%2026-11-18 close
Market Cap
₩149.8B
Turnover
₩500M
Volume
40K
Shares out.
13.1M
PER
8.3×
PBR
0.8×
EPS
₩1,454
Dividend Yield
0.00%

PER, EPS, PBR and BPS are calculated in-house from the last 4 quarters (2025Q4–2026Q3) · Dividend yield is based on ₩0 per share · Prices as of the 2026-11-18 close

01

Report overview

Kolon Life Science: Annual Turnaround, Volatile Quarters

Kolon Life Science returned to annual operating profit in 2025, but its third-quarter 2026 operating profit fell 80.9% from a year earlier, leaving quarterly volatility as the key point to watch.

  1. 1

    On the disclosed 2025 basis, operating profit was KRW 17.6 billion, turning positive from an operating loss of KRW 22.1 billion in 2024, and operating cash flow also turned positive at KRW 10.2 billion.

  2. 2

    The debt ratio fell from 180.9% in 2024 to 56.6% in 2025, with total equity of KRW 584 billion and total liabilities of KRW 330.4 billion at year-end 2025.

  3. 3

    Third-quarter 2026 revenue reached KRW 58 billion, extending a three-quarter run of gains from the fourth-quarter 2025 low, while operating profit was KRW 3.6 billion, down 80.9% year on year.

  4. 4

    The company is widening its RNA therapy raw materials (phosphoramidites) and CDMO business, while patent registrations continue for KLS-3021, an anticancer gene therapy candidate still at the preclinical stage.

  5. 5

    Controlling-shareholder net income over the last four quarters totals KRW 19 billion, and the first quarter of 2026 alone, at KRW 20.8 billion, exceeds that total.

02

Business structure

Kolon Life Science is a bio and pharmaceutical company organized around active pharmaceutical ingredient (API) supply, raw materials for RNA therapeutics, contract development and manufacturing (CDMO), and gene therapy R&D.

Its API business supplies raw materials for anti-inflammatory and analgesic drugs and lipid-lowering treatments to customers in Korea and abroad.

The company says it has received continued quality audit approvals from Japan's PMDA and local pharmaceutical companies, and it has also obtained GMP certification from Brazil's ANVISA.

Its growth push centers on phosphoramidites, a core raw material for RNA therapeutics, where the portfolio now adds modified products and customer-specific development solutions to basic DNA and RNA products.

The CDMO unit covers process development, commercial production and regulatory support, according to the company. In R&D, KLS-3021, an anticancer gene therapy candidate, is the key asset; its production technology patent was first registered in Japan at the end of 2025 and approved in Canada in June 2026.

A preclinical study in triple-negative breast cancer reported in May 2026 showed antitumor effects and long-term anticancer immune memory. KLS-3021 is still preclinical, so it does not yet contribute to revenue.

In CDMO, the company is compared with large contract manufacturers such as Samsung Biologics, while its raw material business competes with API suppliers in Korea and abroad. Kolon Corporation, the largest shareholder, held 24.76 percent as of June 30, 2026.

03

Earnings trend

Quarterly revenue · Operating profit
RevenueOperating profit
Annual revenue · Operating profit
RevenueOperating profit
Quarterly results · Last 5 quarters
QuarterRevenueOperating profitOp. margin
2025Q3₩66.5B₩18.9B28.4%
2025Q4₩44.7B-₩2.7B−6.0%
2026Q1₩49.7B₩2.9B5.9%
2026Q2₩50.6B-₩800M−1.6%
2026Q3₩58B₩3.6B6.2%
Annual results
YearRevenueOperating profitNet income (parent)Op. marginROEDebt-to-equity
2022₩192.4B₩1.6B₩2.1B0.8%1.3%87.3%
2023₩124.6B-₩24.1B-₩30.7B−19.3%−22.3%124.8%
2024₩161.4B-₩22.1B-₩93.1B−13.7%−62.3%180.9%
2025₩209B₩17.6B₩25B8.4%4.3%56.6%

Consolidated basis (financial statements including subsidiaries) · Final figures from DART filings · Net income attributable to owners of the parent · Data as of 2026-11-13

04

Earnings analysis

Annual revenue fell from KRW 192.4 billion in 2022 to KRW 124.6 billion in 2023, a 35.2% decline, then rose 29.5% to KRW 161.4 billion in 2024 and 29.5% again to KRW 209 billion in 2025, a two-year increase following the 2023 low. Among the years 2022 to 2025, 2025 was the largest.

Operating profit moved from KRW 1.63 billion in 2022 to an operating loss of KRW 24.1 billion in 2023, a turn to loss, and the company stayed in loss in 2024 with an operating loss of KRW 22.1 billion, though the loss narrowed.

In 2025 operating profit was KRW 17.6 billion, turning positive, with an operating margin of 8.4%. The operating margin was 0.8% in 2022, -19.3% in 2023 and -13.7% in 2024.

Net income attributable to controlling shareholders swung to a net loss of KRW 30.7 billion in 2023 and KRW 93.1 billion in 2024, which widened the loss, before turning to a KRW 25 billion profit in 2025. Net income including non-controlling interests also reached KRW 25 billion in 2025.

Quarterly, the third quarter of 2025 showed revenue of KRW 66.5 billion, operating profit of KRW 18.9 billion and controlling-shareholder net income of KRW 25.5 billion, while the fourth quarter fell to revenue of KRW 44.7 billion (down 32.7% from the prior quarter), an operating loss of KRW 2.66 billion and a controlling-shareholder net loss of KRW 9.58 billion.

In the first quarter of 2026, revenue was KRW 49.7 billion with operating profit of KRW 2.92 billion and controlling-shareholder net income of KRW 20.8 billion, a return to profit.

The second quarter brought revenue of KRW 50.6 billion but an operating loss of KRW 785 million and a controlling-shareholder net loss of KRW 2.19 billion.

Third-quarter 2026 revenue of KRW 58 billion rose 14.6% from the prior quarter but fell 12.8% from a year earlier, while operating profit of KRW 3.6 billion dropped 80.9% year on year and controlling-shareholder net income of KRW 9.94 billion fell 61.1%.

Operating results alternate between profit and loss from quarter to quarter, so margins are not stable. The detailed causes of quarterly movements and whether any items were one-off should be checked in the notes to the quarterly reports.

05

Industry analysis

The RNA therapeutics market is described as a growing segment, and Kolon Life Science has placed phosphoramidites, a core raw material for this market, at the center of its new supply items.

Industry participants note that global pharmaceutical companies increasingly seek partners that can handle development, manufacturing and regulatory support alongside raw material supply. That trend aligns with the company's strategy of linking its API production and quality control experience to CDMO work.

However, the CDMO market includes Samsung Biologics, which has large facilities and a long track record, so Kolon Life Science sits closer to a mid-sized, raw-material-based player.

Other listed companies in the same sector, such as Celltrion and Alteogen, often earn from product sales or technology licensing, which makes their business models different. The company argues that quality audit approvals in regulated markets such as Japan act as an entry barrier in its API business.

In gene therapy, valuations vary sharply with clinical stage, so the pace of progress for preclinical candidates is a factor in where a company stands within the sector.

06

Outlook

The outlook here follows the business schedule the company has made public. The first pillar is expanding phosphoramidites and CDMO services to overseas customers, and the company outlined plans for a standalone booth at CPHI Worldwide 2026 in Milan in October 2026 to present new supply items and CDMO services.

The second pillar is patent protection for KLS-3021, the anticancer gene therapy candidate, with production technology registrations following in Japan and then Canada.

The third pillar is ESG management: the company joined the UN Global Compact (UNGC) on November 11, 2026, and says it is pursuing a 5% cut in greenhouse gas emissions by 2030. Its first UNGC progress report is scheduled for publication in 2027.

The company also planned to attend BIOHK 2026 in Hong Kong in September 2026 to discuss joint R&D. The weight of the outlook would change if the timing of clinical entry for pipeline assets or the scale of new CDMO contracts were disclosed.

07

Valuation

PER
8.3×
PBR
0.8×
ROE
7.0%
EPS
₩1,454
BPS
₩15,140
Dividend per share
₩0

The price-to-book ratio is below 1x, meaning the share price sits under the company's book net asset value. Year-end 2025 total equity was KRW 584 billion, and market capitalization is smaller than that figure, so the shares trade at a discount to net assets.

The price-earnings multiple, measured against controlling-shareholder net income of KRW 19 billion over the last four quarters, is sensitive to earnings swings because the earnings base is thin.

The first quarter of 2026 alone exceeds that four-quarter total, so the multiple should be read alongside the quarterly trend. The dividend yield is close to zero and sits below the average of the KOSDAQ pharmaceutical sector.

The direction toward recovery since the 2025 return to annual profit is clear, while how far annual profit persists quarter to quarter is the main variable for how the multiple is read.

PER, EPS, PBR and BPS are all calculated in-house (the same method as Naver and Toss) · Dividend yield = cash dividend per share from DART filings (supplemented by KRX) ÷ current price · As of 2026-11-13

08

Bull factors

Annual turnaround and a stronger balance sheet

Operating profit in 2025 was KRW 17.6 billion, turning positive from an operating loss of KRW 22.1 billion in 2024, and operating cash flow also turned positive at KRW 10.2 billion. The debt ratio fell from 180.9% to 56.6%, with total equity of KRW 584 billion at year-end 2025.

Controlling-shareholder net income of KRW 25 billion, a turn to profit, is also part of the disclosed improvement.

Expansion in RNA raw materials and CDMO

The company says it is broadening its phosphoramidite portfolio for RNA therapeutics across basic products, modified products and customer-specific development solutions. It describes its CDMO unit as covering the full cycle from process development to commercial production and regulatory support.

The company presents its existing API production and quality control capabilities as the basis for expanding CDMO work.

Patent expansion and preclinical data for gene therapy

KLS-3021, an anticancer gene therapy candidate, has had its production technology patent registered in Japan at the end of 2025 and in Canada in June 2026. Because it is still preclinical, the value of this pipeline cannot be measured in numbers until clinical results emerge.

09

Bear factors

Sharp drop in third-quarter 2026 operating profit

Third-quarter 2026 revenue rose to KRW 58 billion, but operating profit fell 80.9% year on year to KRW 3.6 billion. Controlling-shareholder net income of KRW 9.94 billion dropped 61.1% from a year earlier. The failure of revenue recovery to carry through to profit is read as a weakness.

Profits and losses alternating by quarter

Operating losses recurred in the fourth quarter of 2025, at KRW 2.66 billion, and the second quarter of 2026, at KRW 785 million. A second-quarter loss sits between profitable first and third quarters of 2026, so the pattern is uneven.

Controlling-shareholder net income of KRW 20.8 billion in the first quarter of 2026 exceeds the four-quarter total of KRW 19 billion, so earnings are concentrated in one quarter.

Accumulated past losses and the durability of profit

After a turn to operating loss in 2023 at KRW 24.1 billion, the company stayed in operating loss in 2024 at KRW 22.1 billion. The 2024 controlling-shareholder net loss of KRW 93.1 billion was large. Whether the 2025 return to profit is structural will need to be judged by the quarterly trend from 2026 onward.

10

Risk factors

Earnings volatility

The operating margin swings between positive and negative from quarter to quarter, so whether annual profit carries into quarterly results is uncertain. The third quarter of 2026 showed that operating profit can fall even as revenue rises, depending on the cost structure. The direction of the earnings trend is hard to pin down until the causes of quarterly moves are clear.

Clinical uncertainty in the pipeline

KLS-3021 is at the preclinical stage, so clinical entry and results will take time and spending. Patent registration does not guarantee commercial success, and preclinical data may not be reproduced in clinical trials. The pace of pipeline progress will shape the company's next growth stage.

Ownership structure and free float

Kolon Corporation was reported to hold 24.76% as of June 30, 2026. Another shareholder table lists the largest shareholder and related parties at 41.84%, showing a high concentration among major holders. The two figures come from different reporting dates and are not compared directly. The ownership structure affects trading volume and the share of freely traded stock.

11

What to watch next

  1. Late March 2027

    The 2026 annual report filing. The key checks are how fourth-quarter 2026 operating results fit into the full-year total and whether the alternating profits and losses from the first three quarters of 2026 translated into annual operating profit.

  2. Mid-May 2027 (statutory deadline for the Q1 quarterly report)

    Whether first-quarter 2027 operating profit is positive. Because a second-quarter 2026 loss followed the first-quarter 2026 profit, whether profits persist quarter to quarter is the test of sustained recovery.

  3. 2027 (month not yet set)

    The planned publication of the first UNGC progress report after joining. It will show whether concrete data on the greenhouse gas reduction target and other ESG items are disclosed for the first time.

12

Overall view

Kolon Life Science turned to annual operating profit of KRW 17.6 billion and controlling-shareholder net income of KRW 25 billion in 2025, and its debt ratio fell to 56.6%, a stronger balance sheet.

However, third-quarter 2026 operating profit of KRW 3.6 billion fell 80.9% year on year, and profits and losses have alternated quarter to quarter, so the durability of earnings is still being tested.

On the business side, the expansion of phosphoramidites and CDMO work and patent registrations for the KLS-3021 gene therapy candidate are presented as medium-term pillars. Still, KLS-3021 is preclinical, and the KRW 19 billion four-quarter controlling-shareholder net income leans heavily on the first quarter of 2026.

On valuation, the price-to-book ratio is below 1x and market capitalization is smaller than total equity, but whether this signals a durable earnings recovery will become clearer in the 2027 quarterly results.

The next checkpoints are annual operating profit in the 2026 annual report and whether first-quarter 2027 operating profit is positive. Taken together, the picture is a company in which a return to profit coexists with quarterly volatility.

13

Sources

  1. Korea Exchange (KRX) — Prices · Market Cap · Volume
  2. FSS electronic disclosure system (DART) — Financial statements · Dividend filings
Show 16 more articles and sources
  1. jasoseol.com
  2. thebionews.net
  3. etoday.co.kr
  4. view.asiae.co.kr
  5. thebionews.net
  6. sedaily.com
  7. view.asiae.co.kr
  8. hankyung.com
  9. kpanews.co.kr
  10. markets.hankyung.com
  11. littlebproject.com
  12. comp.fnguide.com
  13. investing.com
  14. news.mt.co.kr
  15. judal.co.kr
  16. kr.investing.com

Report written 2026-11-14 · Data as of 2026-11-13

This content is AI analysis of market data and web search results, provided for information only. It is not a solicitation or recommendation to invest. Investment decisions and their consequences are the investor's own responsibility. Data may be delayed or contain errors.

Other reports in this industry

View industry analysis